Statistics from Altmetric.com
The following information has been produced for Veterinary Record by the Veterinary Medicines Directorate (VMD) to provide an update for veterinary surgeons on recent changes to marketing authorisations for veterinary medicines in the UK and other relevant issues
THE points below highlight changes in marketing authorisations that may have a significant impact on veterinary surgeons' prescribing decisions.
New marketing authorisations
The following new marketing authorisations have been issued during May 2011. There were two new products authorised in this period containing an active substance not previously included in authorised veterinary medicinal products in the UK:
■ Zuprevo 180 mg/ml solution for injection for cattle. This contains tildipirosin, a new macrolide authorised for the treatment and prevention of bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to tildipirosin.
■ Zuprevo 40 mg/ml solution for injection for pigs. This contains tildipirosin, a new macrolide authorised for the treatment and prevention of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and Haemophilus parasuis sensitive to tildipirosin.
Other new marketing authorisations issued and/or published during May 2011 were:
■ Closiver 5 mg/ml + 200 mg/ml pour-on solution …